Press Releases

Date Title and Summary
Toggle Summary Accuray Expands CyberKnife® System Versatility with Integration of RaySearch's RayStation Treatment Planning System
Treatment Planning for the CyberKnife System and Other Radiation Therapy Devices Can Now be Performed Using the Same Software Solution SUNNYVALE, Calif. , June 16, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the launch of RayStation* treatment planning support for the
Toggle Summary Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System SUNNYVALE, Calif. , June 10, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark certification for its ClearRT ™ helical
Toggle Summary Accuray Announces New $120 Million Credit Facility
Refinancing Significantly Reduces Interest Rate and Extends Maturity with Increased Operational Flexibility SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) today announced it has entered into a new five-year $80 million term loan and $40 million revolving
Toggle Summary Accuray Announces Convertible Notes Exchange and Subscription
SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (the "2022 Notes") to exchange an aggregate of $82.1 million
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol , M.D., Ph.D., the company's new Chief Medical & Technology Officer. As a material inducement to Dr.
Toggle Summary Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
WILKES-BARRE, Pa. and SUNNYVALE, Calif. , May 3, 2021 /PRNewswire/ --   Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer Accuray Incorporated's (NASDAQ: ARAY) newest Synchrony ®  technology on both the CyberKnife ® S7™  and
Toggle Summary Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
- American Association of Physicists in Medicine (AAPM) Grand Challenge MATCH event was designed to evaluate the potential to track lung tumor motion without fiducial markers in real-time during radiation therapy - Results demonstrate exceptional accuracy is achievable with the Accuray-only
Toggle Summary Accuray Reports Third Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif. , April 27, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021 .     Third Quarter Fiscal 2021 Summary Net revenue of $102.6 million including $24.9 million of system revenue in
Toggle Summary Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer
SUNNYVALE, Calif. , April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY ) announced today the appointment of Jean-Philippe Pignol , M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021 . In this new role, Dr.
Toggle Summary Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch
Exceptional, Fan-beam Imaging for the Radixact® System Increases Radiation Treatment Options SUNNYVALE, Calif. , April 22, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT ™ helical fan-beam kVCT imaging* capability has now been in clinical use

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at